Malignant Solid Tumor
50
8
13
22
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.0%
8 terminated out of 50 trials
73.3%
-13.2% vs benchmark
0%
0 trials in Phase 3/4
45%
10 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (50)
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies